Collegium Pharma Also Gets A "Pass"

Collegium Pharmaceutical (COLL) develops and markets medicines for pain management, focused largely on extended release formulations of addictive opioid-based drugs. Currently, the firm sells 3 drugs, each contributing about 30% of revenue. Xtampza ER is an extended release version of oxycodone. Nucynta ER is a similar formulation of tapentadol, another powerful opioid. Belbuca is a form of buprenorphine, a synthetic opioid that can also be highly addictive. I have a few concerns with investing in this one. First, after the recent purchase of Ironshore to add ADHD drug Journay ER, Collegium will have a substantial amount of debt and only about a 2x interest coverage ratio (that's risky). Second, there is board room drama, with former CEO Joe Ciaffoni forced out in May by founder Michael Heffernan. And finally, about 1/3rd of current sales are at risk in the next few years as Nucynta goes off-patent. Just too many issues with this one. I'm passing on adding it to the Watch List.

Watch List

RDDT 7.71%
NTNX 31.52%
CRWD 63.06%
SE 29.38%
SNOW 7.59%
APPF 4.88%
PINS -23.24%

Buy List

SEMR -38.26%
TSM -38.57%
GOOG -51.98%
NYAX -58.66%
MSFT -31.00%
ODD -31.84%
ASR -28.02%
FLYW -38.06%
HRMY -54.53%
YOU -35.24%
ABNB -32.20%
MELI -29.43%
ADBE -40.48%

Hold List

VTEX -18.40%
ZETA -23.56%
CELH 34.60%
TOST 11.93%
CPNG -15.62%
HIMS -16.74%
PAYC -21.31%
MNDY 6.93%
GLBE -22.43%
ZS 27.08%
V -5.03%
ADSK -3.10%
NOW -3.65%
FTNT -5.29%
TEAM -4.39%